← Omeros overview

Omeros vs Capricor Therapeutics: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Omeros Corporation (OMER)

Q3 2026
▼2▲1

Omeros Hit by EU Setback and Lawsuits, Then Rival's Trial Failure Lifts Shares

  • EU rejection triggers securities investigations Multiple law firms are investigating Omeros for possible securities fraud after European regulators rejected its drug narsoplimab for a rare blood disorder. This legal cloud could lead to costly class actions and keeps pressure on the stock, as investors worry about management's disclosures.

    This is a new negative development that directly weighs on OMER's price and investor confidence.

  • Analyst cuts price target on EU rejection H.C. Wainwright lowered its price target for Omeros from $40 to $33, removing the European market opportunity for narsoplimab and factoring in higher research spending. The analyst still rates the stock a Buy, but the cut reflects a smaller potential payoff.

    This shows a concrete reassessment of OMER's value following the EU setback, which can influence investor expectations.

  • Rival's trial failure boosts Omeros' competitive position AstraZeneca's competing drug Ultomiris failed a late-stage trial in the same rare blood disorder that Omeros' Yartemlea treats. This removes a major competitive threat, making it easier for Omeros to grow Yartemlea sales in the U.S., and the stock jumped on the news.

    This is a new positive catalyst that directly improves OMER's commercial outlook and drove a sharp share price increase.

July 2026
▼2▲1

Omeros Hit by EU Setback and Lawsuits, Then Rival's Trial Failure Lifts Shares

  • EU rejection triggers securities investigations Multiple law firms are investigating Omeros for possible securities fraud after European regulators rejected its drug narsoplimab for a rare blood disorder. This legal cloud could lead to costly class actions and keeps pressure on the stock, as investors worry about management's disclosures.

    This is a new negative development that directly weighs on OMER's price and investor confidence.

  • Analyst cuts price target on EU rejection H.C. Wainwright lowered its price target for Omeros from $40 to $33, removing the European market opportunity for narsoplimab and factoring in higher research spending. The analyst still rates the stock a Buy, but the cut reflects a smaller potential payoff.

    This shows a concrete reassessment of OMER's value following the EU setback, which can influence investor expectations.

  • Rival's trial failure boosts Omeros' competitive position AstraZeneca's competing drug Ultomiris failed a late-stage trial in the same rare blood disorder that Omeros' Yartemlea treats. This removes a major competitive threat, making it easier for Omeros to grow Yartemlea sales in the U.S., and the stock jumped on the news.

    This is a new positive catalyst that directly improves OMER's commercial outlook and drove a sharp share price increase.

Latest
▼2▲1

Omeros Hit by EU Setback and Lawsuits, Then Rival's Trial Failure Lifts Shares

  • EU rejection triggers securities investigations Multiple law firms are investigating Omeros for possible securities fraud after European regulators rejected its drug narsoplimab for a rare blood disorder. This legal cloud could lead to costly class actions and keeps pressure on the stock, as investors worry about management's disclosures.

    This is a new negative development that directly weighs on OMER's price and investor confidence.

  • Analyst cuts price target on EU rejection H.C. Wainwright lowered its price target for Omeros from $40 to $33, removing the European market opportunity for narsoplimab and factoring in higher research spending. The analyst still rates the stock a Buy, but the cut reflects a smaller potential payoff.

    This shows a concrete reassessment of OMER's value following the EU setback, which can influence investor expectations.

  • Rival's trial failure boosts Omeros' competitive position AstraZeneca's competing drug Ultomiris failed a late-stage trial in the same rare blood disorder that Omeros' Yartemlea treats. This removes a major competitive threat, making it easier for Omeros to grow Yartemlea sales in the U.S., and the stock jumped on the news.

    This is a new positive catalyst that directly improves OMER's commercial outlook and drove a sharp share price increase.

Capricor Therapeutics Inc (CAPR)

Q3 2026
▼3

FDA Panel Rejects Capricor's Deramiocel; Securities Fraud Investigations Mount

  • FDA Briefing Document Questions Deramiocel Efficacy On July 27, the FDA released a briefing document stating that Capricor's Duchenne therapy Deramiocel lacked substantial evidence of effectiveness and had an unfavorable benefit-risk profile. This threatens the drug's approval and caused the stock to plunge 64.5% to $7.00.

    This is the core event that triggered the stock crash and all subsequent fallout.

  • FDA Advisory Committee Votes Against Deramiocel On July 30, an FDA advisory committee voted 3 to 9 that Deramiocel is not effective for Duchenne cardiomyopathy. This raises serious doubts about approval ahead of the August 22 PDUFA date, pushing the stock down further.

    The panel vote is a major new negative development that directly impacts the likelihood of FDA approval.

  • Multiple Securities Fraud Investigations Launched Several law firms (Kirby McInerney, Bragar Eagel & Squire, Hagens Berman, Lowey Dannenberg, Holzer & Holzer, Glancy Prongay) have opened investigations into whether Capricor misled investors about Deramiocel's trial results. These probes add legal uncertainty and could lead to lawsuits, weighing on the stock.

    The investigations are a new consequence of the FDA news and create ongoing legal overhang for the stock.

July 2026
▼3

FDA Panel Rejects Capricor's Deramiocel; Securities Fraud Investigations Mount

  • FDA Briefing Document Questions Deramiocel Efficacy On July 27, the FDA released a briefing document stating that Capricor's Duchenne therapy Deramiocel lacked substantial evidence of effectiveness and had an unfavorable benefit-risk profile. This threatens the drug's approval and caused the stock to plunge 64.5% to $7.00.

    This is the core event that triggered the stock crash and all subsequent fallout.

  • FDA Advisory Committee Votes Against Deramiocel On July 30, an FDA advisory committee voted 3 to 9 that Deramiocel is not effective for Duchenne cardiomyopathy. This raises serious doubts about approval ahead of the August 22 PDUFA date, pushing the stock down further.

    The panel vote is a major new negative development that directly impacts the likelihood of FDA approval.

  • Multiple Securities Fraud Investigations Launched Several law firms (Kirby McInerney, Bragar Eagel & Squire, Hagens Berman, Lowey Dannenberg, Holzer & Holzer, Glancy Prongay) have opened investigations into whether Capricor misled investors about Deramiocel's trial results. These probes add legal uncertainty and could lead to lawsuits, weighing on the stock.

    The investigations are a new consequence of the FDA news and create ongoing legal overhang for the stock.

Latest
▼3

FDA Panel Rejects Capricor's Deramiocel; Securities Fraud Investigations Mount

  • FDA Briefing Document Questions Deramiocel Efficacy On July 27, the FDA released a briefing document stating that Capricor's Duchenne therapy Deramiocel lacked substantial evidence of effectiveness and had an unfavorable benefit-risk profile. This threatens the drug's approval and caused the stock to plunge 64.5% to $7.00.

    This is the core event that triggered the stock crash and all subsequent fallout.

  • FDA Advisory Committee Votes Against Deramiocel On July 30, an FDA advisory committee voted 3 to 9 that Deramiocel is not effective for Duchenne cardiomyopathy. This raises serious doubts about approval ahead of the August 22 PDUFA date, pushing the stock down further.

    The panel vote is a major new negative development that directly impacts the likelihood of FDA approval.

  • Multiple Securities Fraud Investigations Launched Several law firms (Kirby McInerney, Bragar Eagel & Squire, Hagens Berman, Lowey Dannenberg, Holzer & Holzer, Glancy Prongay) have opened investigations into whether Capricor misled investors about Deramiocel's trial results. These probes add legal uncertainty and could lead to lawsuits, weighing on the stock.

    The investigations are a new consequence of the FDA news and create ongoing legal overhang for the stock.

© 2026 MarketIVWhy